



NovoBiome announces investment from eureKARE SA

eureKARE SA will bring long-term expertise, financial and operational support to NovoBiome

Alexandre Mouradian and Rodolphe Besserve will join NovoBiome's Supervisory Board

Paris, France – 18 May 2021: NovoBiome ("the Company"), a drug discovery company focused on the critical nexus of liver, intestinal diseases and the gut microbiome, today announced investment from eureKARE SA, a pioneering new company focused on financing and building next generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology, into its capital.

NovoBiome develops breakthrough Live Biotherapeutics Products (LBPs)¹ targeting the microbiome-gut-liver axis. NovoBiome is also building a comprehensive, disruptive *ex-vivo* research and discovery platform, NovoSift® to analyze the symbiotic relationship between the microbiota and the human intestine.

eureKARE is a recently founded company focused on financing and building next generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology. eureKARE is guided by influential founder, Alexandre Mouradian, along with a pan-European team led by renowned biotech expert Rodolphe Besserve. Alexandre and Rodolphe will join NovoBiome's Supervisory Board.

Pierre-Yves Mousset, Chief Executive Officer of NovoBiome, said: "As NovoBiome sets out on its mission to develop breakthrough treatments in the area of the microbiome gut-liver axis, we are delighted to receive the support of the capable team at eureKARE. We look forward to working closely with the team moving forward and I am happy to welcome both Alexandre and Rodolphe to the NovoBiome Supervisory Board."

"Beyond the world-renowned expertise of its experts, Hervé Blottière and Joël Doré, NovoBiome has enormous potential to identify and develop new therapeutic perspectives based on the understanding of the relationship between the gut microbiota and its host. In this context, eureKARE's investment in NovoBiome is an obvious choice as its activity targets the core of eureKARE's business philosophy." **commented Rodolphe Besserve, CEO of eureKARE.**

-End-

About NovoBiome

¹ LBPs are medicinal products containing living micro-organisms such as bacteria or yeasts, which have a positive influence on the health and physiology of the host. Source: Ph. Eur. Monograph 3053 (EDQM, 2019)

NovoBiome is a drug discovery company focused on the critical nexus of liver, intestinal diseases and the gut microbiome. It is developing breakthrough Live Biotherapeutics Products (LBPs), a novel and emerging class of drugs containing living micro-organisms that have a positive influence on the health and physiology of the host. NovoBiome's first LBP drug candidate, ADC-001, targets potential first-in-class therapies for hepatic conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH). The Company is developing an *ex-vivo* research and discovery platform, NovoSift®, designed to mimic human intestinal physiology that will unlock new insights into disease pathophysiology, novel drug targets, compounds and LBP drug candidates.

NovoBiome is headquartered in France. For more information, please visit: www.novobiome.eu

About eureKARE

eureKARE is a pioneering new company focused on financing and building next generation biotechnology companies in the cutting-edge fields of the microbiome and synthetic biology. eureKARE has a two-step investment approach to deliver long-term value creation. The Company supports transformational research by creating and financing new companies out of high value European science through its biotech start-up studios eureKABIOME (Microbiome) and eureKASYNBIO (Synthetic biology). The Company also intends to invest in more mature biotech companies and will systematically propose to offer some liquidity to early investors, thereby addressing a critical need in the European biotech field. Guided by its influential founder, Alexandre Mouradian, and a pan-European team, eureKARE has a rapidly growing portfolio of companies that have the potential to disrupt the life sciences industry.

eureKARE is headquartered in Luxembourg, with a presence in France & Belgium. For more information visit: <https://eurekare.eu>

Contact

NovoBiome

Pierre-Yves Mousset, Chief Executive Officer

+33 (0) 616 310 400

py.mousset@novobiome.eu

eureKARE SA

Marina Shapochnik, Head Investor Relations

marina.shapochnik@eurekare.eu

Consilium Strategic Communications

Amber Fennell, Jonathan Birt, Melissa Gardiner, Carina Jurs

+44 (0) 203 709 5000

eurekare@consilium-comms.com